Spots Global Cancer Trial Database for locally advanced or metastatic breast cancer

Every month we try and update this database with for locally advanced or metastatic breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Halaven Post-Marketing Surveillance (PMS)	NCT02441764	Breast Cancer		-	Eisai Inc.
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC	NCT03952325	Breast Cancer	Tesetaxel Tesetaxel Tesetaxel Nivolumab Pembrolizumab Atezolizumab Tesetaxel	18 Years -	Odonate Therapeutics, Inc.
Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer	NCT00669565	Carcinoma Breas...	Bavituximab	18 Years -	Peregrine Pharmaceuticals
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer	NCT05212701	Fatigue Locally Advance...	Reparixin Placebo	18 Years -	Dompé Farmaceutici S.p.A
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer	NCT05744687	Locally Advance...	SPH4336 Tablets... SPH4336 Tablets...	18 Years - 75 Years	Shanghai Pharmaceuticals Holding Co., Ltd
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)	NCT05296798	Locally Advance...	Phesgo Giredestrant Docetaxel Paclitaxel LHRH Agonist Optional Endocr...	18 Years -	Hoffmann-La Roche
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy	NCT03027245	Locally Advance...	Eribulin	18 Years -	Eisai Inc.
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)	NCT05296798	Locally Advance...	Phesgo Giredestrant Docetaxel Paclitaxel LHRH Agonist Optional Endocr...	18 Years -	Hoffmann-La Roche
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants	NCT03437083	Locally Advance...	Eribulin mesyla...	-	Eisai Inc.
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer	NCT05054751	Locally Advance...	GB491+ Fulvestr... Placebo+Fulvest...	18 Years -	Genor Biopharma Co., Ltd.
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants	NCT03437083	Locally Advance...	Eribulin mesyla...	-	Eisai Inc.
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer	NCT05212701	Fatigue Locally Advance...	Reparixin Placebo	18 Years -	Dompé Farmaceutici S.p.A
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer	NCT05212701	Fatigue Locally Advance...	Reparixin Placebo	18 Years -	Dompé Farmaceutici S.p.A
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer	NCT01156753	Breast Cancer	CDX-011 "Investigator's...	18 Years -	Celldex Therapeutics
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer	NCT05430399	Breast Neoplasm... Locally Advance...	utidelone docetaxel	18 Years -	Sun Yat-sen University
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer	NCT05860465	Locally Advance...	SPH4336 Tablets SPH4336 Tablets...	18 Years - 75 Years	Shanghai Pharmaceuticals Holding Co., Ltd
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC	NCT06439771	Locally Advance...	YL202 should be...	18 Years - 75 Years	MediLink Therapeutics (Suzhou) Co., Ltd.
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC	NCT03952325	Breast Cancer	Tesetaxel Tesetaxel Tesetaxel Nivolumab Pembrolizumab Atezolizumab Tesetaxel	18 Years -	Odonate Therapeutics, Inc.

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: